Opendata, web and dolomites

HOPE SIGNED

Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Immune Checkpoint NR2F6

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HOPE project word cloud

Explore the words cloud of the HOPE project. It provides you a very rough idea of what is the project "HOPE" about.

startegies    entities    mission    delineate    crispr    distal    rendering    adverse    experimentally    prevalent    tools    clinical    pd    intrinsic    inhibitors    profoundly    nr2f6    tumour    employing    clinically    axis    lung    prevention    cancer    recurrence    latter    prevents    limitations    metastases    team    pronged    reveal    node    signatures    rejecting    chronic    supports    biological    first    inseparable    validate    signalling    combination    cas9    human    resistance    screening    prerequisite    immunity    immunological    clinic    reducing    biochemical    tumours    technologies    inflammation    mechanisms    functional    therapeutic    anti    strategies    progression    functions    influence    genetic    preventive    successful    events    complexity    initiation    either    proteomic    generation    cells    overcome    host    protective    immune    checkpoint    genomic    site    lymphocyte    epidemiologically    elucidated    oncology    effector    risk    pkc    cell    shown    therapy    potentially    network    poorly    nsclc    transcriptomic    perturbation    molecular    predisposition    microenvironment    crossroads    spread    organs    combinatorial   

Project "HOPE" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE UNIVERSITAT INNSBRUCK 

Organization address
address: CHRISTOPH PROBST PLATZ 1
city: INNSBRUCK
postcode: 6020
website: www.i-med.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 2˙484˙325 €
 EC max contribution 2˙484˙325 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAT INNSBRUCK AT (INNSBRUCK) coordinator 2˙484˙325.00

Map

 Project objective

'Because of its biological complexity, cancer is still poorly understood. Chronic inflammation has been shown, both experimentally and epidemiologically, to be a predisposition to, and also an inseparable aspect of clinically prevalent cancer entities. Therefore, a detailed understanding of both tumour and immune cell functions in cancer progression is a prerequisite for more successful therapeutic startegies. My team was the first to reveal the lymphocyte-intrinsic PKC/NR2F6 axis as an essential signalling node at the crossroads between inflammation and cancer. It is the mission of this project to identify molecular signatures that influence the risk of developing tumours employing established research tools and state-of-the-art genetic, biochemical, proteomic and transcriptomic as well as large scale CRISPR/Cas9 perturbation screening-based functional genomic technologies. Defining this as yet poorly elucidated effector pathway with its profoundly relevant role would enable development of preventive and immune-therapeutic strategies against NSCLC lung cancer and potentially also against other entities. Our three-pronged approach to achieve this goal is to: (i) delineate biological and clinical properties of the immunological PKC/NR2F6 network, (ii) validate NR2F6 as an immune-oncology combination target needed to overcome limitations to 'first generation anti-PD-1 checkpoint inhibitors' rendering T cells capable of rejecting tumours and their metastases at distal organs and (iii) exploit human combinatorial T cell therapy concepts for prevention of immune-related adverse events as well as of tumour recurrence by reducing opportunities for the tumour to develop resistance in the clinic. Insight into the functions of NR2F6 pathway and involved mechanisms is a prerequisite for understanding how the microenvironment at the tumour site either supports tumour growth and spread or prevents tumour initiation and progression, the latter by host-protective cancer immunity.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HOPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HOPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

TALNET (2020)

Transparent Aluminium Networks

Read More  

TOROS (2019)

A Theory-Oriented Real-Time Operating System for Temporally Sound Cyber-Physical Systems

Read More